Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Cardiovascular
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
16 March 2010
Merck / Portola Pharmaceuticals ' investigational Factor Xa inhibiting anticoagulant betrixaban was associated with significantly less clinically relevant bleeding than warfarin when given at 40mg/day to patients with atrial fibrillation, show new ...
ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
15 March 2010
Hypolipaemic fenofibrates such as Abbott s' TriCor, its next-generation Trilipix and generics, do not improve cardiovascular outcomes in patients with type 2 diabetes when used in combination with simvastatin (Merck & Co's lipid-lowering Zocor). The ...
Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
15 March 2010
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the ...
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the ...
Philippines makes more medicine price cuts for pharma
09 March 2010
The Philippines government has announced a second wave of price cuts in the medicines sector under the government-mediated access price (GMAP) programme. Most reductions will come into effect on March 31st, while others will be implemented at a ...
 
Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
Challenges and opportunities in the Philippine pharma market
08 January 2010
On the face of it, the Philippines should be an attractive market for multinational pharmaceutical companies. There is a well-established healthcare system that covers the majority of the population ...
 
Amarin focused on CV disease to pump new life into company
24 February 2010
The fundraising that saved Amarin from financial woes last years appear to have given the company a new lease of life. Its interim CEO Dr Declan Doogan told Scrip of his confidence for the company's ...
Anti-obesity drugs: an inventor's perspective
20 November 2009
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of ...
Xention looks to ion technology to jump start safer treatments
30 October 2009
While the patent cliff looms ever closer for big pharma, some smaller companies are not looking to untreated diseases to develop the new blockbuster but to conditions that are already catered for, ...
 
Questions linger over US comparative effectiveness funding
24 February 2009
The economic stimulus bill signed into law by US President Barack Obama on February 17th provides a $1.1 billion bolus to government agencies for comparative effectiveness research on medical ...
Life under FDAAA: Four months of post-approval studies and REMS
01 August 2008
The FDA has not hesitated to use its new safety powers since they took effect on March 25th. A review of original and supplemental NDA and BLA approval letters on the FDA's website indicates that, ...
 
Vitamin D and the vasculature: can we teach an old drug new tricks?
13 May 2009
Background: Vitamin D is a steroid hormone known for its role in regulating levels of calcium and phosphorus. Vitamin D has important autocrine/paracrine roles and it is involved in vascular biology. ...
Autophagy: a target for therapeutic interventions in myocardial pathophysiology
01 December 2008
Background: Autophagy is a major degradative and highly conserved process in eukaryotic cells that is activated by stress signals. This self-cannibalisation is activated as a response to changing ...
A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration
01 December 2008
Objective: Amplification of inflammatory response in the non-infarct area plays an important role in the pathogenesis of ventricular remodeling after myocardial ischemia. Activation of nuclear ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm